⌘K
Sahajanand Medical Technologies is a medical device company specializing in cardiovascular products like Drug-Eluting Stents (DES), PTCA balloons, TAVI systems, and Occluders. The company has demonstrated strong revenue and profit growth, turning around from a loss-making position in FY24 to significant profitability in FY26. The IPO is entirely an Offer for Sale, meaning the company will not receive any proceeds. While the company operates in a growing industry and exhibits robust financial performance, its valuation appears expensive compared to peers, and there are notable litigation and regulatory risks.
The business operates in a growing industry with a robust product portfolio and clear growth strategies. Market sentiment, particularly from institutional investors, is strong. However, the valuation is notably high compared to peers, and there are several critical and high risks, including litigation, regulatory issues, and the 100% OFS structure.
While QIB and NII subscriptions were strong, the moderate GMP and high valuation suggest limited listing upside. The 100% OFS nature also dampens enthusiasm for immediate gains.
The high valuation and existing risks (litigation, regulatory) could cap short-term performance. Any negative news could lead to price corrections. Strong fundamentals might provide support, but the premium pricing is a concern.
The company operates in a growing industry with a strong product portfolio and clear growth strategies. Despite the current high valuation, its consistent financial growth and innovation potential could deliver long-term value, provided risks are managed effectively.
Listing-day performance is not available yet. It will appear here once this IPO has listed and results are recorded.
| Category | Shares Offered | % of Issue | Share |
|---|---|---|---|
| QIB | 67,86,058 | 49.1% | |
| NII (HNI) | 20,35,817 | 14.73% | |
| Retail | 47,50,241 | 34.37% | |
| Employee | 2,50,000 | 1.81% |
| Investor | |||
|---|---|---|---|
| NIPPON INDIA SMALL CAP FUND | 11,45,090 | ₹39.39 Cr | 28.12% |
| DSP HEALTHCARE FUND | 5,90,992 | ₹20.33 Cr | 14.51% |
| WHITEOAK CAPITAL FLEXI CAP FUND | 1,84,341 | ₹6.34 Cr | 4.53% |
| WHITEOAK CAPITAL MULTI ASSET ALLOCATION FUND | 87,204 | ₹3 Cr | 2.14% |
| WHITEOAK CAPITAL PHARMA & HEALTHCARE FUND | 1,45,340 | ₹5 Cr | 3.57% |
| INVESCO INDIA PHARMA & HEALTHCARE FUND | 4,36,063 | ₹15 Cr | 10.71% |
| UTI HEALTHCARE FUND | 4,36,063 | ₹15 Cr | 10.71% |
| ALLIANZ GLOBAL INVESTORS FUND-ALLIANZ INDIA EQUITY | 4,36,063 | ₹15 Cr | 10.71% |
| TATA AIA LIFE INSURANCE CO.LTD.-WHOLE LIFE AGGRESSIVE GROWTH FUND-ULIF 010 04/01/07 WLA 110 | 2,90,723 | ₹10 Cr | 7.14% |
| NATIXIS INTERNATIONAL FUNDS (LUX) I-LOOMIS SAYLES GLOBAL EMERGING MARKETS EQUITY FUND | 3,19,755 | ₹11 Cr | 7.85% |
Grey-market premium history is not yet available for this issue.
Premium gain of 5.96% over issue price.
Strong revenue and profit growth, with a turnaround from loss to significant profitability.
Improving EBITDA and PAT margins.
Low Debt/Equity ratio, indicating manageable leverage.
Specialized product portfolio in cardiovascular medical devices with strong clinical evidence.
Clear growth strategies including market penetration, new product launches, and M&A.
Operating in a growing medical device industry.
Strong institutional demand reflected in QIB and NII subscription figures.
Presence of reputable anchor investors.
Successful launch of next-generation TAVI systems, deeper penetration in international markets, strategic acquisitions, and sustained high industry growth.
Consistent execution of current growth strategies, stable industry growth, and effective management of operational and regulatory risks.
Increased competition, adverse regulatory changes, product recalls, failure to retain key personnel, or significant impact from litigation.
Positive: Strong and consistent revenue and profit growth (PAT turnaround from loss).
Concern: High post-IPO P/E of 57.91x, making it expensive compared to peers (36.35x - 51.4x) and industry average (43.87x).
Advisory: reported profit not backed by operating cash flow (paper-profit risk)
Listing-gain vs long-term: Neutral / Neutral.